Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIL-214 co-administered with routine vaccines in healthy infants
NCT05836012Phase 3Completed
- Sponsor
- HilleVax
- Start
- Jun 2023
- Primary completion
- Jan 2024
- Modality
- Recombinant Protein Vaccines
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in norovirus gastroenteritis comparing HIL-214 + Routine with Placebo + Routine (2 arms). Primary endpoints: Immune Response to the Licensed Pediatric DTaP-Hib-IPV-HepB Vaccine Co-administered With HIL-214 Compared to Placebo, Immune Response to the Licensed Pediatric Pneumococcal 13 Valent (PCV13) Vaccine Co-administered With HIL-214 Compared to Placebo and 1 more. Started Jun 2023; status: completed.
02
Drugs
NoV GI.1/GII.4 bivalent VLP vaccine
03
Conditions
norovirus gastroenteritis
Beyond the preview
Go deeper on NCT05836012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05836012.